Tenderwize
Back to tender search

Open-house drug rebate agreement for sarilumab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Sep 30, 2027 · 314 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Sarilumab, ATC L04AC14

54/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

54 / 100

Complexity

61 / 100

Risk factors

The notice does not state the contract value, expected demand, quantities, rebate structure, or other commercial parame...

The deadline for the initial 1 December 2025 contract start was 31 October 2025, which is earlier than the current date.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Sep 30, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under sections 130a(8) and 130c(1) SGB V for medicines containing Sarilumab, ATC L04AC14.
  • Open-house model with uniform contract conditions for all participating pharmaceutical companies and no individual negotiations.
Show full summary

Open-house, non-exclusive pharmaceutical rebate agreements for Sarilumab (ATC L04AC14) offered by AOK Rheinland-Pfalz/Saarland to all interested pharmaceutical companies meeting the stated product and documentation conditions. There is no competitive selection or individual negotiation. The maximum contract period is 24 months, with monthly entry opportunities, but contracts may end automatically if exclusive rebate agreements replace them. No contract value is stated. Procurement documents were not provided for analysis; only the extracted TED XML notice was available.

Risks

The notice does not state the contract value, expected demand, quantities, rebate structure, or other commercial parame...

The deadline for the initial 1 December 2025 contract start was 31 October 2025, which is earlier than the current date.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicants must be pharmaceutical companies.
  • Only authorised medicines that are marketable in Germany may be supplied under the agreement.
  • If marketability is shown in the Lauer-Taxe, that listing is accepted as proof.

Buyer

Lots (1)

LOT-0001

Sarilumab pharmaceutical rebate agreement

Non-exclusive open-house rebate agreements for authorised and marketable Sarilumab medicines in Germany. Contracts use uniform conditions, do not involve a selection decision or individual negotiations, and may be concluded monthly during the open-house period. Medicines included on the BfArM list under section 35(5a) SGB V for paediatric medicines are excluded.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Nov 2025 - Nov 2027

Category

Pharmaceutical products

Deadline

Deadline Sep 30, 2027

Procurement Details

Publication date
19 Oct 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
687428-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy